Cue Biopharma, Inc. (CUE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 8M 16M 24M Q1 '18: 191K Q2 '18: 172K Q3 '18: 449K Q4 '18: 330.6K Q1 '19: 370K Q2 '19: 1.1M Q3 '19: 984K Q4 '19: 1M Q1 '20: 900K Q2 '20: 1.1M Q3 '20: 704K Q4 '20: 475.3K Q1 '21: 1.6M Q2 '21: 2.7M Q3 '21: 2.4M Q4 '21: 8.3M Q1 '22: 1M Q2 '22: 26K Q3 '22: 68K Q4 '22: 151K Q1 '23: 187K Q2 '23: 1.4M Q3 '23: 2.1M Q4 '23: 1.8M Q1 '24: 1.7M Q2 '24: 2.7M Q3 '24: 3.3M Q4 '24: 1.6M Q1 '25: 421K Q2 '25: 3M Q3 '25: 2.1M Q4 '25: 21.9M Q1 '26: 5.7M Q2 '26: 7.9M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q1 '17: -3.4M Q2 '17: -4.4M Q3 '17: -5M Q4 '17: -10.4M Q1 '18: -7.5M Q2 '18: -7.5M Q3 '18: -12.8M Q4 '18: -11M Q1 '19: -11.4M Q2 '19: -9.2M Q3 '19: -7.1M Q4 '19: -9M Q1 '20: -13M Q2 '20: -10.9M Q3 '20: -10.1M Q4 '20: -11M Q1 '21: -12.5M Q2 '21: -10.3M Q3 '21: -13M Q4 '21: -7.9M Q1 '22: -14.2M Q2 '22: -13.1M Q3 '22: -11M Q4 '22: -14.9M Q1 '23: -13.4M Q2 '23: -13.5M Q3 '23: -11.4M Q4 '23: -13.8M Q1 '24: -12.7M Q2 '24: -10.4M Q3 '24: -8.8M Q4 '24: -9.6M Q1 '25: -12.3M Q2 '25: -8.6M Q3 '25: -7.6M Q4 '25: 2M Q1 '26: -5.4M Q2 '26: -87.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-180M -120M -60M 0 60M 120M 180M Q1 '17: -3.4M Q2 '17: -4.4M Q3 '17: -5M Q4 '17: -10.4M Q1 '18: -7.5M Q2 '18: -7.3M Q2 '18: -7.3M Q3 '18: -12.6M Q3 '18: -12.6M Q4 '18: -11.6M Q1 '19: -11.3M Q2 '19: -9.5M Q2 '19: -9.5M Q3 '19: -7M Q3 '19: -7M Q4 '19: -8.9M Q1 '20: -12.8M Q2 '20: -10.8M Q3 '20: -10M Q4 '20: -11.1M Q1 '21: -12.5M Q2 '21: -10.3M Q3 '21: -13M Q4 '21: -8.4M Q1 '22: -14.3M Q2 '22: -13.2M Q3 '22: -11M Q4 '22: -14.6M Q1 '23: -13.1M Q2 '23: -13.2M Q3 '23: -11M Q4 '23: -13.4M Q1 '24: -12.3M Q2 '24: -10.2M Q3 '24: -8.7M Q4 '24: -9.5M Q1 '25: -12.3M Q2 '25: -8.5M Q3 '25: -7.4M Q4 '25: 1.6M Q1 '26: -5.2M Q2 '26: -153.1M Q2 '18 Q2 '19 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-30M -20M -10M 0 10M 20M 30M Q1 '17: -3.5M Q2 '17: -3.2M Q3 '17: -3.7M Q4 '17: -1.8M Q1 '18: -9.8M Q2 '18: -6.5M Q3 '18: -6.3M Q4 '18: -3.9M Q1 '19: -8.5M Q2 '19: -6.7M Q3 '19: -9.2M Q4 '19: -6.4M Q1 '20: -10.9M Q2 '20: -6.9M Q3 '20: -7.7M Q4 '20: -7M Q1 '21: -11.8M Q2 '21: -9.8M Q3 '21: -6.6M Q4 '21: -10.6M Q1 '22: -11.6M Q2 '22: -12.8M Q3 '22: -6.9M Q4 '22: -10.5M Q1 '23: -10.8M Q2 '23: -10.4M Q3 '23: -7.8M Q4 '23: -11M Q1 '24: -9.8M Q2 '24: -10M Q3 '24: -7.5M Q4 '24: -9M Q1 '25: -8.2M Q2 '25: -3.4M Q3 '25: -9M Q4 '25: -1.1M Q1 '26: -10.9M Q2 '26: -29M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-30M -20M -10M 0 10M 20M 30M Q1 '17: -4M Q2 '17: -3.4M Q3 '17: -3.9M Q4 '17: -1.9M Q1 '18: -10.4M Q2 '18: -7.2M Q3 '18: -6.6M Q4 '18: -4M Q1 '19: -8.5M Q2 '19: -6.7M Q3 '19: -9.2M Q4 '19: -6.4M Q3 '20: -8M Q4 '20: -7.1M Q1 '21: -12.4M Q2 '21: -10M Q3 '21: -6.6M Q4 '21: -10.6M Q1 '22: -11.6M Q2 '22: -12.9M Q3 '22: -6.9M Q4 '22: -10.5M Q1 '23: -10.8M Q2 '23: -10.4M Q3 '23: -7.8M Q4 '23: -11M Q1 '24: -9.8M Q2 '24: -10M Q3 '24: -7.5M Q4 '24: -9M Q1 '25: -8.3M Q2 '25: -3.4M Q3 '25: -9M Q4 '25: -1.1M Q1 '26: -11.1M Q2 '26: -29M Q1 '17 Q2 '18 Q3 '19 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q3 '21: 31.3M Q1 '22: 32.6M Q2 '22: 35.4M Q3 '22: 35.4M Q1 '23: 44.7M Q2 '23: 44.8M Q3 '23: 46.4M Q1 '24: 49.5M Q2 '24: 50.2M Q3 '24: 51.2M Q1 '25: 2.5M Q2 '25: 3.2M Q3 '25: 100.9M Q1 '26: 4.8M Q2 '26: 6.3M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-21.00 -14.00 -7.00 0.00 7.00 14.00 21.00 Q4 '17: -2.15 Q1 '18: -2.21 Q2 '18: -2.16 Q3 '18: -2.31 Q4 '18: -1.93 Q1 '19: -2.10 Q2 '19: -2.20 Q3 '19: -1.89 Q4 '19: -1.67 Q1 '20: -1.61 Q2 '20: -1.53 Q3 '20: -1.56 Q4 '20: -1.56 Q1 '21: -1.49 Q2 '21: -1.44 Q3 '21: -1.51 Q4 '21: -1.40 Q1 '22: -1.43 Q2 '22: -1.47 Q3 '22: -1.37 Q4 '22: -1.50 Q1 '23: -1.35 Q2 '23: -1.27 Q3 '23: -1.20 Q4 '23: -1.11 Q1 '24: -1.07 Q2 '24: -0.98 Q3 '24: -0.91 Q4 '24: -0.72 Q1 '25: -5.42 Q2 '25: -7.89 Q3 '25: -7.79 Q4 '25: -0.28 Q1 '26: 3.59 Q2 '26: -17.88 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.